MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202641048049 A) filed by Mohan Babu University, Tirupati, Andhra Pradesh, on April 15, for 'studies on preformulation characteristics and production of pazopanib nanoparticles.'
Inventor(s) include Mrs. M. Keerthi; and Dr. Shanmugham Vippamakula.
The application for the patent was published on May 1, under issue no. 18/2026.
According to the abstract released by the Intellectual Property India: "Pazopanib is an oral multi-targeted tyrosine kinase inhibitor used in the treatment of renal cell carcinoma. Despite its clinical efficacy, its poor aqueous solubility and low bioavailability significantly limit its therapeutic potential. The present study was undertaken to overcome these challenges by formulating Pazopanib-loaded nanoparticles, following detailed preformulation studies.The preformulation phase involved physicochemical characterization of Pazopanib, including solubility, pH, melting point,compatibility studies with excipients using techniques like FTIR and DSC. Based on the data obtained, suitable polymeric carriers were selected to enhance the solubility and stability of the drug. Nanoparticles were prepared using a modified nanoprecipitation technique with biocompatible polymers such as PLGA and PVA. The formulation was optimized based on particle size, polydispersity index (PDI), zeta potential, and drug loading capacity. The optimized nanoparticles were further characterized by SEM for surface morphology.The results demonstrated that the prepared Pazopanib nanoparticles exhibited a significant reduction in particle size, improved drug encapsulation efficiency, and controlled release kinetics, thereby enhancing the solubility and potential bioavailability of the drug."
Disclaimer: Curated by HT Syndication.
